A novel, highly accurate and cost-effective genetic panel

for the risk assessment and early diagnosis of neurodegenerative diseases empowered by Artificial Intelligence

A novel, highly accurate and cost-effective genetic panel

for the risk assessment and early diagnosis of neurodegenerative diseases empowered by Artificial Intelligence

FIRALIS

About Firalis :

Firalis is a biotechnology company specialized in biomarker R&D with cutting edge analytical technologies and actionable outcomes.
FIRALIS is based in Huningue (FR) in the heart of the three borders France, Germany and Switzerland.

Role of Firalis :

· Lead developer of the NeuroDeGene® platform, with development and integration of the genetic panel and AI software.

· Providing biobank samples and proprietary datasets.

· Leading regulatory planning and commercialization strategies.

· Project management and Intellectual Property protection.

Inserm U1329

About Inserm U1329

Strasbourg Translational Neuroscience and Psychiatry.
100 people, 3 research teams
Team 3: focusing on ALS and FTD
Loic Dupuis’ team focuses on non-motor symptoms of ALS (weight loss, sleep defects) and genetic basis.

Role of Inserm U1329

We will apply the NeuroDeGene panel to multiple datasets of ALS and other neurodegenerative diseases available in house

CHU Lille

About CHU Lille

Benchmark university hospital for primary care, teaching, innovation and research

4 strategic areas: Neurosciences, Oncology, Metabolic & Cardiovascular diseases, Inflammation, Infection & Immunity
Complex of 10 Specialized Hospital, 16 clinical and medico-technical deprtamentd and employing 15,395 people including 3,626 practicing or junior doctors
In 2022, Lille University Hospital was sponsoring 592 clinical studies and entering 212 academic and 186 industrial new clinical trials, 8 000+ enrolled patients
Certified Lille biobank manages more than 230 study protocol, allowing 7,350 samples receipts and 6,000 samples outlets per year (2019)
Fourth position in the national ranking (MERRI data 2018)
Involved in 15 European grants (FP7, IMI, H2020, Interreg)

Role of CHU Lille:

Give access to PULSE cohort, a multimodal and longitudinal cohort of de novo ALS patients followed every three months
Improve the clinical utility of NeuroDeGene biomarkers

GENERA

About GENERA

Established in 2013, İstanbul, Gen Era is a leading product and service provider in diagnostics and life sciences. Gen Era offers a broad range of molecular diagnostic tests, reagents, as well as instruments of high technology and quality. With the power of distributorship supported by high skilled and experienced team, Gen Era succeeded to alter the understanding of laboratory services in Turkey and became a pioneer in diagnostics.

Role of GENERA

Laboratory testing and validation of diagnostic workflows.
Market access insights and support for Turkey and surrounding regions (especially for Commonwealth of Independent States region).

Hacettepe University

About Hacettepe University

Hacettepe University is a forerunner academic institution in Turkey in the field of biomedical research.
More than 300 thematic research laboratories are active in various academic units and 3 hospitals serving about 1 million outpatients with more than 1000 beds for the inpatients. Hacettepe allocates more than 10% of its total investment budget on R&D infrastructure.
According to Times Higher Education rankings (THE) Hacettepe University is ranked within the first 500 Universities in the field of bio-medicine and health.
Hacettepe produced 2270 SCI/E indexed publications in 2023 in biomedical and health sciences category fore-running in pediatrics, oncology, neurology, pharmacology, surgery, cardiology, hematology, radiology, rheumatology and immunology.

Role of Hacettepe University

Clinical Trials and Sample Collection: Lead the clinical trials by recruiting patients, collecting samples, and documenting clinical outcomes.
Clinical Expertise and Advisory: Offer clinical insights into neurodegenerative disease manifestations within the local population, aiding in the interpretation of trial results and the adjustment of diagnostic parameters.
Machine Learning / AI model implementation

A novel, highly accurate and cost-effective genetic panel

A novel, highly accurate and cost-effective genetic panel

Project Partners

FIRALIS

Inserm U1329

CHU Lille

GENERA

Hacettepe University

Contact Us

Drop us a line!

A novel, highly accurate and cost-effective genetic panel

A novel, highly accurate and cost-effective genetic panel

Project Partners

FIRALIS

Inserm U1329

CHU Lille

GENERA

Hacettepe University

Contact Us

Drop us a line!

Bu web sitesinde çerez kullanılır.